Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus

Elisa H. Fleming, Eliana E. Ochoa, Joan Nichols, M. Kerry O'Banion, Alan R. Salkind, Norbert J. Roberts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Both respiratory syncytial virus (RSV) and influenza A virus (IAV) may infect human peripheral blood mononuclear leukocytes (PBMC) during the immune response to viral challenge as the cells are recruited to the respiratory tract. The current studies demonstrated differences in PBMC responses to the two viruses very early after exposure, including reduced fos protein and CD69 expression and IL-2 production by RSV-exposed T lymphocytes. Exposure to RSV resulted in reduced lymphocyte proliferation despite evidence of a virus-specific T lymphocyte frequency equivalent to that for influenza virus. Reduced RSV-induced proliferation was not due to apoptosis, which was itself reduced relative to that of influenza virus-exposed T lymphocytes. The data indicate that differential immune responses to RSV and influenza virus are determined early after exposure of human PBMC and support the concept that the anamnestic immune response that might prevent clinically evident reinfection is attenuated very soon after exposure to RSV. Thus, candidate RSV vaccines should be expected to reduce but not prevent clinical illness upon subsequent infection by RSV. Furthermore, effective therapeutic agents for RSV are likely to be needed, especially for high-risk populations, even after vaccine development.

Original languageEnglish (US)
Pages (from-to)26-33
Number of pages8
JournalJournal of Medical Virology
Volume90
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Respiratory Syncytial Viruses
Orthomyxoviridae
Lymphocytes
Mononuclear Leukocytes
T-Lymphocytes
Respiratory Syncytial Virus Vaccines
Viruses
Respiratory Syncytial Virus Infections
Influenza A virus
Respiratory System
Interleukin-2
Vaccines
Apoptosis
Population

Keywords

  • human lymphocytes
  • influenza virus
  • lymphocyte activation
  • lymphocyte proliferation
  • respiratory syncytial virus

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus. / Fleming, Elisa H.; Ochoa, Eliana E.; Nichols, Joan; O'Banion, M. Kerry; Salkind, Alan R.; Roberts, Norbert J.

In: Journal of Medical Virology, Vol. 90, No. 1, 01.01.2018, p. 26-33.

Research output: Contribution to journalArticle

Fleming, Elisa H. ; Ochoa, Eliana E. ; Nichols, Joan ; O'Banion, M. Kerry ; Salkind, Alan R. ; Roberts, Norbert J. / Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus. In: Journal of Medical Virology. 2018 ; Vol. 90, No. 1. pp. 26-33.
@article{9e01ad786ffc4c5e80db6e454c4ded27,
title = "Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus",
abstract = "Both respiratory syncytial virus (RSV) and influenza A virus (IAV) may infect human peripheral blood mononuclear leukocytes (PBMC) during the immune response to viral challenge as the cells are recruited to the respiratory tract. The current studies demonstrated differences in PBMC responses to the two viruses very early after exposure, including reduced fos protein and CD69 expression and IL-2 production by RSV-exposed T lymphocytes. Exposure to RSV resulted in reduced lymphocyte proliferation despite evidence of a virus-specific T lymphocyte frequency equivalent to that for influenza virus. Reduced RSV-induced proliferation was not due to apoptosis, which was itself reduced relative to that of influenza virus-exposed T lymphocytes. The data indicate that differential immune responses to RSV and influenza virus are determined early after exposure of human PBMC and support the concept that the anamnestic immune response that might prevent clinically evident reinfection is attenuated very soon after exposure to RSV. Thus, candidate RSV vaccines should be expected to reduce but not prevent clinical illness upon subsequent infection by RSV. Furthermore, effective therapeutic agents for RSV are likely to be needed, especially for high-risk populations, even after vaccine development.",
keywords = "human lymphocytes, influenza virus, lymphocyte activation, lymphocyte proliferation, respiratory syncytial virus",
author = "Fleming, {Elisa H.} and Ochoa, {Eliana E.} and Joan Nichols and O'Banion, {M. Kerry} and Salkind, {Alan R.} and Roberts, {Norbert J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jmv.24917",
language = "English (US)",
volume = "90",
pages = "26--33",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Reduced activation and proliferation of human lymphocytes exposed to respiratory syncytial virus compared to cells exposed to influenza virus

AU - Fleming, Elisa H.

AU - Ochoa, Eliana E.

AU - Nichols, Joan

AU - O'Banion, M. Kerry

AU - Salkind, Alan R.

AU - Roberts, Norbert J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Both respiratory syncytial virus (RSV) and influenza A virus (IAV) may infect human peripheral blood mononuclear leukocytes (PBMC) during the immune response to viral challenge as the cells are recruited to the respiratory tract. The current studies demonstrated differences in PBMC responses to the two viruses very early after exposure, including reduced fos protein and CD69 expression and IL-2 production by RSV-exposed T lymphocytes. Exposure to RSV resulted in reduced lymphocyte proliferation despite evidence of a virus-specific T lymphocyte frequency equivalent to that for influenza virus. Reduced RSV-induced proliferation was not due to apoptosis, which was itself reduced relative to that of influenza virus-exposed T lymphocytes. The data indicate that differential immune responses to RSV and influenza virus are determined early after exposure of human PBMC and support the concept that the anamnestic immune response that might prevent clinically evident reinfection is attenuated very soon after exposure to RSV. Thus, candidate RSV vaccines should be expected to reduce but not prevent clinical illness upon subsequent infection by RSV. Furthermore, effective therapeutic agents for RSV are likely to be needed, especially for high-risk populations, even after vaccine development.

AB - Both respiratory syncytial virus (RSV) and influenza A virus (IAV) may infect human peripheral blood mononuclear leukocytes (PBMC) during the immune response to viral challenge as the cells are recruited to the respiratory tract. The current studies demonstrated differences in PBMC responses to the two viruses very early after exposure, including reduced fos protein and CD69 expression and IL-2 production by RSV-exposed T lymphocytes. Exposure to RSV resulted in reduced lymphocyte proliferation despite evidence of a virus-specific T lymphocyte frequency equivalent to that for influenza virus. Reduced RSV-induced proliferation was not due to apoptosis, which was itself reduced relative to that of influenza virus-exposed T lymphocytes. The data indicate that differential immune responses to RSV and influenza virus are determined early after exposure of human PBMC and support the concept that the anamnestic immune response that might prevent clinically evident reinfection is attenuated very soon after exposure to RSV. Thus, candidate RSV vaccines should be expected to reduce but not prevent clinical illness upon subsequent infection by RSV. Furthermore, effective therapeutic agents for RSV are likely to be needed, especially for high-risk populations, even after vaccine development.

KW - human lymphocytes

KW - influenza virus

KW - lymphocyte activation

KW - lymphocyte proliferation

KW - respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=85034040648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034040648&partnerID=8YFLogxK

U2 - 10.1002/jmv.24917

DO - 10.1002/jmv.24917

M3 - Article

VL - 90

SP - 26

EP - 33

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 1

ER -